Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Calquence

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 27,744Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abbvie Submitted sNDA for Venetoclax in Untreated CLL
    Abbvie Submitted sNDA for Venetoclax in Untreated CLL

    30 Jul 2025

    // PRESS RELEASE

    https://news.abbvie.com/2025-07-29-AbbVie-Submits-for-U-S-FDA-Approval-of-Combination-Treatment-of-VENCLEXTA-R-venetoclax-and-Acalabrutinib-for-Previously-Untreated-Patients-with-Chronic-Lymphocytic-Leukemia-CLL

    PRESS RELEASE
    30 Jul 2025
    Share Share
    EU Approves Calquence-Based Regimens for CLL Patients
    EU Approves Calquence-Based Regimens for CLL Patients

    07 Jun 2025

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html

    PRESS RELEASE
    07 Jun 2025
    Share Share
    FDA Approves Acalabrutinib for Mantle Cell Lymphoma
    FDA Approves Acalabrutinib for Mantle Cell Lymphoma

    17 Jan 2025

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html

    PRESS RELEASE
    17 Jan 2025
    Share Share
    CALQUENCE® Gets US Priority Review For Mantle Cell Lymphoma
    CALQUENCE® Gets US Priority Review For Mantle Cell Lymphoma

    03 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241003958806/en

    BUSINESSWIRE
    03 Oct 2024
    Share Share
    AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia
    AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia

    30 Jul 2024

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html

    PRESS RELEASE
    30 Jul 2024
    Share Share
    CALQUENCE Plus Chemoimmunotherapy Reduced MCL Progression Risk
    CALQUENCE Plus Chemoimmunotherapy Reduced MCL Progression Risk

    16 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240616853829/en

    BUSINESSWIRE
    16 Jun 2024
    Share Share